Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

Overview of attention for article published in JAMA Oncology, November 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#30 of 3,320)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Altmetric has seen 6 posts from 6 blogs.

Analysis of 1,000 patients in the MINDACT trial identifies patients with ultra-low risk for distant recurrence. These patients…

DCIS: many breast ‘cancers’ behave benignly – e.g. some 94% survival at 20 years after diagnosis with no symptoms https://jamanet…

A molecular test can pinpoint which patients will have a very low risk of death from breast cancer

For the first time, magnetic resonance imaging (MRI) is being used to guide ‘frozen needles’ to tumours in patients with…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity, including 2 additional blog posts.